cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Fulcrum Therapeutics Inc
7 own
4 watching
Current Price
$0
$-0.6
(-4.68%)
logo-fulc
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
667.28M
52-Week High
52-Week High
24.79
52-Week Low
52-Week Low
3.21
Average Volume
Average Volume
0.71M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization667.28M
icon52-Week High24.79
icon52-Week Low3.21
iconAverage Volume0.71M
iconDividend Yield--
iconP/E Ratio--
What does the Fulcrum Therapeutics Inc do?
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Fulcrum Therapeutics Inc make?
News & Events about Fulcrum Therapeutics Inc.
Zolmax
9days ago
Fulcrum Therapeutics (NASDAQ:FULC Get Rating) had its price target trimmed by Oppenheimer from $30.00 to $26.00 in a report issued on Thursday, The Fly reports. FULC has been the subject of a number of other research reports. Morgan Stanley increased their target price on Fulcrum Therapeutics from $...
Globe Newswire
13days ago
CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the pricing of an underwritten public offering of 9,615,384 ...
Ticker Report
22days ago
Fulcrum Therapeutics, Inc. (NASDAQ:FULC Get Rating) major shareholder Ra Capital Management, L.P. purchased 180,703 shares of the businesss stock in a transaction dated Wednesday, January 4th. The stock was bought at an average cost of $7.28 per share, with a total value of $1,315,517...
Zolmax
1month ago
Fulcrum Therapeutics, Inc. (NASDAQ:FULC Get Rating) major shareholder Ra Capital Management, L.P. purchased 1,341,420 shares of the companys stock in a transaction dated Friday, December 16th. The stock was bought at an average cost of $5.42 per share, for a total transaction of $7,270,496.40. ...
Frequently Asked Questions
Frequently Asked Questions
What is Fulcrum Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Fulcrum Therapeutics Inc shares?
plus_minus_icon
How can I buy Fulcrum Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Fulcrum Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Fulcrum Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Fulcrum Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Fulcrum Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Fulcrum Therapeutics Inc?
plus_minus_icon
What percentage is Fulcrum Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Fulcrum Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.6
(-4.68%)
logo-fulc
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$12.38
$0.20 (1.60 %)
Allakos Inc
Allakos Inc
$7.32
$0.10 (1.32 %)
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
$21.15
$-0.14 (-0.66 %)
Alector Inc
Alector Inc
$8.74
$0.09 (1.10 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$12.38
$0.20 (1.60 %)
Allakos Inc
Allakos Inc
$7.32
$0.10 (1.32 %)
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
$21.15
$-0.14 (-0.66 %)
Alector Inc
Alector Inc
$8.74
$0.09 (1.10 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00